Case Study: The Client accelerates PROTAC R&D prioritization with L.E.K. Consulting

the client identifies 100+ PROTAC targets with LEK Consulting

The client, a pharmaceutical company, engaged LEK Consulting to address the challenge of prioritizing R&D investment for its next-generation proteolysis-targeting chimeras (PROTACs) platform. Faced with a broad range of modality options and growing competition, the client needed a robust analysis to identify the most valuable clinical opportunities across various therapeutic areas.

LEK Consulting developed a strategic roadmap by defining the PROTAC clinical strategy, evaluating the client's value proposition, and characterizing the competitive landscape. The solution provided the client with a list of over 100 attractive near-term targets and a framework for opportunity assessment. The results included actionable steps to de-risk R&D investments, a target selection strategy for faster clinical ramp-up, and defined milestones to support future investment decisions.